Patrys (PABA.F) Stock Overview

Develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. More details

PABA.F fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Makes less than USD$1m in revenue (A$100K)

Does not have a meaningful market cap ($20M)

PABA.F Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,774 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

491,774 investors already sharing narratives

View all narratives

Patrys Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Patrys
Historical stock prices
Current Share Price	AU$0.06
52 Week High	AU$0.06
52 Week Low	AU$0.05
Beta	1.07
1 Month Change	0%
3 Month Change	20.00%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-52.00%

Recent updates

Shareholder Returns

	PABA.F	US Biotechs	US Market
7D	0%	-2.3%	0.8%
1Y	n/a	35.8%	20.6%

Return vs Industry: Insufficient data to determine how PABA.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how PABA.F performed against the US Market.

Price Volatility

Is PABA.F's price volatile compared to industry and market?
PABA.F volatility
PABA.F Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

Stable Share Price: PABA.F's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine PABA.F's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2006	n/a	Sam South	patrys.com

Patrys Limited, together with its subsidiaries, develops antibody technologies for the treatment of cancer and NETosis-driven inflammatory diseases. It develops PAT-DX1, a small antibody fragment derived from a humanized version of the binding domain from the original mouse deoxymab antibody 3E10; and PAT-DX3 for treating primary and secondary brain cancers, and metastases that are associated with NETosis, or in combination with DNA damaging agents, such as radiation and other chemotherapy drugs. The company was incorporated in 2006 and is based in Nedlands, Australia.

Patrys Limited Fundamentals Summary

How do Patrys's earnings and revenue compare to its market cap?
PABA.F fundamental statistics
Market cap	US$20.20m
Earnings (TTM)	-US$3.18m
Revenue (TTM)	US$70.73k

285.6x

P/S Ratio

-6.3x

P/E Ratio

Is PABA.F overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PABA.F income statement (TTM)
Revenue	AU$100.38k
Cost of Revenue	AU$0
Gross Profit	AU$100.38k
Other Expenses	AU$4.61m
Earnings	-AU$4.51m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0068
Gross Margin	100.00%
Net Profit Margin	-4,497.20%
Debt/Equity Ratio	0%

How did PABA.F perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/14 12:02
End of Day Share Price	2026/03/17 00:00
Earnings	2025/12/31
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Patrys Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Matthijs Smith	Lodge Partners Pty Ltd.

Patrys LimitedOTCPK:PABA.F Stock Report